Somatuline® Autogel® & Somatuline® LA 30mg
lanreotide
Description
Somatuline® Autogel® Lanreotide (I.N.N.) 60 mg, 90 mg or 120 mg (as acetate), Solution for injection. White to off-white, translucent and viscous supersaturated solution in a pre-filled syringe, ready for use.
Somatuline® LA 30mg Lanreotide (I.N.N., B.A.N.) 0.030 g, Powder for suspension for injection.
Active substance
Lanreotide
Indications
Somatuline® Autogel® is indicated for:
- The treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels and where possible to normalise these values.
- The treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumours.
Somatuline® LA 30mg is indicated for:
- The treatment of acromegaly when the circulating levels of growth hormone remain abnormal after surgery and/or radiotherapy.
- The treatment of thyrotrophic adenomas when the circulating level of thyroid stimulating hormone remains inappropriately high after surgery and/or radiotherapy.
- The relief of symptoms associated with neuroendocrine (particularly carcinoid) tumours.
Further information
Somatuline Autogel Summary of product characteristics
Somatuline Autogel Patient information leaflet
